Physician profile
Rebecca Allison Garfinkle
NPI 1003993353
$1,058.89
in general payments reported to CMS, 2019-2025
9 companies · $299 in 2025
The $299 reported for 2025 was more than what a typical Neurodevelopmental Disabilities (Pediatrics) provider received nationally (typical 2025 total: $136).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $85.67 · 2021: $43.32 · 2022: $156 · 2023: $299 · 2024: $175 · 2025: $299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $773.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $773.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $371.24 | 2019-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $255.57 | 2021-2025 | Qelbree, Qelbree |
| Tris Pharma INC | $181.44 | 2022-2025 | Dyanavel Xr, Onyda Xr |
| Corium, LLC | $71.66 | 2022-2025 | Azstarys |
| Collegium Pharmaceutical, INC. | $68.64 | 2025 | Jornay Pm |
| Greenwich Biosciences, INC. | $46.43 | 2019 | |
| Vertical Pharmaceuticals, LLC | $22.94 | 2025 | Relexxii |
| Neos Therapeutics, Lp | $22.19 | 2025 | Cotempla Xr-Odt |
| Neurelis, INC. | $18.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rebecca Garfinkle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.